-
Subject Areas on Research
-
A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors.
-
Angiopoietin-1 enhances skeletal muscle regeneration in mice.
-
Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide.
-
Angiotensin II promotes development of the renal microcirculation through AT1 receptors.
-
Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.
-
Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.
-
Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP.
-
Cross-talk between endothelial and breast cancer cells regulates reciprocal expression of angiogenic factors in vitro.
-
Early Endothelial Activation Precedes Glycocalyx Degradation and Microvascular Dysfunction in Experimentally Induced Plasmodium falciparum and Plasmodium vivax Infection.
-
Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
-
Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation.
-
Infection-Induced Vascular Permeability Aids Mycobacterial Growth.
-
Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer.
-
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.
-
Intravenous fluid resuscitation is associated with septic endothelial glycocalyx degradation.
-
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors.
-
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance).
-
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
-
Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.
-
Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.
-
Tie1: an orphan receptor provides context for angiopoietin-2/Tie2 signaling.
-
VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling.
-
Variants in angiopoietin-2 (ANGPT2) contribute to variation in nocturnal oxyhaemoglobin saturation level.